Compugen Ltd.
| NASDAQ: CGEN | Healthcare / Biotechnology / Israel |
| 0.6627 | -0.0063 | -0.94% | Vol 108.16K | 1Y Perf -44.25% |
| Nov 30th, 2023 16:00 DELAYED |
| BID | 0.6515 | ASK | 0.7000 | ||
| Open | 0.6600 | Previous Close | 0.6690 | ||
| Pre-Market | - | After-Market | 0.67 | ||
| - - | 0.01 1.10% |
| Target Price | 7.13 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 975.90 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★+ 48.59 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★ 37.96 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 13.83 | Earnings Rating | Strong Buy | |
| Market Cap | 57.40M | Earnings Date | 7th Nov 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.26 | |
| Beta | 2.67 |
Today's Price Range 0.65270.6700 | 52W Range 0.53001.49 | 5 Year PE Ratio Range -13.10-6.90 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 3.53% | ||
| 1 Month | -12.80% | ||
| 3 Months | -41.87% | ||
| 6 Months | -35.66% | ||
| 1 Year | -44.25% | ||
| 3 Years | -94.85% | ||
| 5 Years | -80.85% | ||
| 10 Years | -93.62% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -29.59 | |||
ROE last 12 Months | -48.00 | |||
ROA (5Y Avg) | -14.32 | |||
ROA last 12 Months | -38.84 | |||
ROC (5Y Avg) | -53.64 | |||
ROC last 12 Months | -44.32 | |||
Return on invested Capital Q | -14.01 | |||
Return on invested Capital Y | -8.34 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.80 | ||||
| 0.94 | ||||
| 10.87 | ||||
| - | ||||
| -3.60 | ||||
| -0.35 | ||||
| 0.94 | ||||
| 0.92 | ||||
| -15 536 900.00 | ||||
| Forward PE | -1.45 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.20 | ||||
| 6.20 | ||||
| 0.02 | ||||
| 0.02 | ||||
| - | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 89.60 | ||||
| -579.10 | ||||
| -571.60 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| -78.92 | ||||
| -11.11 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.09 | -0.11 | -22.22 |
| Q02 2023 | -0.13 | -0.11 | 15.38 |
| Q01 2023 | -0.12 | -0.11 | 8.33 |
| Q04 2022 | -0.14 | -0.04 | 71.43 |
| Q03 2022 | -0.13 | -0.14 | -7.69 |
| Q02 2022 | -0.12 | -0.11 | 8.33 |
| Q01 2022 | -0.12 | -0.11 | 8.33 |
| Q04 2021 | -0.15 | -0.10 | 33.33 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | 0.00 | 100.00 | Positive |
| 12/2023 QR | 0.00 | 100.00 | Positive |
| 12/2023 FY | -0.31 | 8.82 | Positive |
| 12/2024 FY | -0.44 | -2.33 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | -0.09 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 108.16K |
| Shares Outstanding | 88.23K |
| Shares Float | 77.09M |
| Trades Count | 413 |
| Dollar Volume | 71.33K |
| Avg. Volume | 178.25K |
| Avg. Weekly Volume | 149.74K |
| Avg. Monthly Volume | 214.87K |
| Avg. Quarterly Volume | 170.13K |
Compugen Ltd. (NASDAQ: CGEN) stock closed at 0.6627 per share at the end of the most recent trading day (a -0.94% change compared to the prior day closing price) with a volume of 108.16K shares and market capitalization of 58.47M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 68 people. Compugen Ltd. CEO is Anat Cohen-Dayag.
The one-year performance of Compugen Ltd. stock is -44.25%, while year-to-date (YTD) performance is -7.41%. CGEN stock has a five-year performance of -80.85%. Its 52-week range is between 0.53 and 1.4897, which gives CGEN stock a 52-week price range ratio of 13.83%
Compugen Ltd. currently has a PE ratio of -1.80, a price-to-book (PB) ratio of 0.94, a price-to-sale (PS) ratio of 10.87, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -38.84%, a ROC of -44.32% and a ROE of -48.00%. The company’s profit margin is -%, its EBITDA margin is -571.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Compugen Ltd., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. Compugen Ltd.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Compugen Ltd. is Strong Buy (1), with a target price of $7.13, which is +975.90% compared to the current price. The earnings rating for Compugen Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Compugen Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Compugen Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 22.71, ATR14 : 0.05, CCI20 : 8.87, Chaikin Money Flow : -0.18, MACD : -0.03, Money Flow Index : 43.40, ROC : 14.85, RSI : 46.08, STOCH (14,3) : 88.47, STOCH RSI : 0.82, UO : 55.92, Williams %R : -11.53), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Compugen Ltd. in the last 12-months were:
Compugen Ltd.
Compugen Ltd is a therapeutic discovery company. It is involved in the business of using its predictive discovery infrastructure to identify novel drug targets and develop biologics. The firm's therapeutic pipeline mainly consists of early-stage immuno-oncology programs aimed at harnessing the immune system to fight cancer. It focuses on immune checkpoint target candidates which are predicted to serve drug targets for cancer immunotherapies addressing various cancer types and also autoimmune diseases.
CEO: Anat Cohen-Dayag
Telephone: +972 37658585
Address: 26 Harokmim Street, Holon 5885849, , IL
Number of employees: 68
TipRanks News for CGEN
Wed, 23 Aug 2023 13:57 GMT Truist optimistic on Compugens approach after Roche data leak
- TipRanks. All rights reserved.
